Kevin Li, M.D.

Kevin is a Partner on the Frazier Life Sciences team focused on investments in public and late-stage private companies.

Kevin joined the Frazier Life Sciences team in 2021 and invests in public and late-stage private companies for the Frazier Life Sciences Public Fund (FLSPF). He co-led the fund’s investment in Scorpion Therapeutics (acquired by Lilly) and currently serves as a board observer at 35Pharma and GondolaBio.

Kevin was previously a resident physician in Internal Medicine at Stanford and a consultant at McKinsey & Company, where he focused on corporate strategy, growth, and M&A in the hospital services and pharmaceutical industries.

Kevin received his M.D. from Stanford University and his B.S. from Yale University, where he graduated summa cum laude in Molecular Biophysics and Biochemistry and was a member of Phi Beta Kappa.